Core Viewpoint - Zhaoke Ophthalmology (06622) has expanded its global commercialization footprint by granting exclusive rights for its core presbyopia treatment drug BRIMOCHOL PF to AFT Pharmaceuticals in Singapore and Kenso in Vietnam, enhancing its market presence in eight countries [1] Group 1: Company Developments - Zhaoke Ophthalmology's stock price increased by over 7% during trading, currently up 3.44% at HKD 3.61, with a trading volume of HKD 11.43 million [1] - The company has now extended its global commercialization rights to include markets in South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan, Singapore, and Vietnam [1] Group 2: Partnerships - AFT Pharmaceuticals, based in New Zealand, has been granted exclusive distribution rights in Singapore and operates in over 125 countries [1] - Kenso, a Japanese private pharmaceutical company, has been awarded exclusive distribution rights in Vietnam and focuses on enhancing vision health through original pharmaceuticals [1]
兆科眼科-B盘中涨超7% 公司扩大与AFT的合作至新加坡 与千寿达成越南合作协议